nivolumab
nivolumab at a dose of 3 mg per kilogram of body weight every 2 weeks, Reductions in the nivolumab dose were not permitted.
docetaxel
docetaxel at a dose of 75 mg per square meter of body-surface area every 3 weeks
non squamous - mNSCLC - L2 - all population
Patients with known EGFR mutation or ALK translocation were allowed to have received or be receiving an additional line of tyrosine kinase inhibitor therapy,
open-label
NA
P3/ two sided and one interim analysis. Hierarchical testing procedure with secondary endpoints
IA results (stopped)/this trial meet its primary endpoint of OS and secondary endpoint ORR but not PFS